TICKERNERD
Menu
EBSEBSHealthcare · Drug Manufacturers - Specialty & Generic

EBS Stock Forecast: Emergent BioSolutions, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.09
+5.60% on the day

The 3 Wall Street analysts covering Emergent BioSolutions, Inc. hold a median 12-month price target of $11 — +116.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$260.5M
Ticker Nerd rank
90 / 100
Median analyst target
$11
Analysts covering
3
Total return, dividends reinvested
1W
+10.9%
1M
−33.5%
YTD
−58.8%
1Y
−45.4%
From 52W high
−63.4%
From 52W low
+14.4%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EBS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Emergent BioSolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Accruals
99
Issuance
98
Quality
95
Size
65
Revisions
50
Momentum
35
Growth
35
Volatility
23

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (23): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EBS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EBS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26EBSHigh $12Median $11Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy0 Hold1 Sell
Low $10Median $11High $12

The green dot is the last close — the median target sits +116.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026HC Wainwright & Co.MaintainsBuy$12 → $10
9 Mar 2026HC Wainwright & Co.MaintainsBuy—
9 Mar 2026HC Wainwright & Co.MaintainsBuy$15 → $12
16 Dec 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
21 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024HC Wainwright & Co.InitiatesBuy—
7 Nov 2024BenchmarkMaintainsBuy—
13 Sept 2024Rodman & RenshawReiteratesBuy—
22 Aug 2024Rodman & RenshawInitiatesBuy—
16 Aug 2024BenchmarkReiteratesBuy—
9 Aug 2024BenchmarkReiteratesBuy—
3 July 2024BenchmarkReiteratesBuy—
2 July 2024BenchmarkReiteratesBuy—
24 June 2024BenchmarkReiteratesBuy—
21 June 2024BenchmarkReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EBS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

EBS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−62.1%
Analysts raising
1
Analysts cutting
0
Fundamentals

Emergent BioSolutions, Inc. (EBS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.6×

Cheaper than 61% of US stocks

Price / sales
0.3×

Cheaper than 88% of US stocks

Price / book
0.8×

Cheaper than 81% of US stocks

EV / EBITDA
3.1×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
66.3%

Higher than 90% of US stocks

Earnings growth (YoY)
74.1%

Higher than 81% of US stocks

Gross margin
57.2%

Higher than 70% of US stocks

Operating margin
28.3%

Higher than 86% of US stocks

Net margin
−23.0%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−40.3%

Higher than 24% of US stocks

Return on assets
6.9%

Higher than 85% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EBS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
EBSEmergent BioSolutions, Inc.$260.5M
90
ACBAurora Cannabis, Inc.$255.2M
34
AKBAAkebia Therapeutics, Inc.$242.9M
75
ANIKAnika Therapeutics, Inc.$291.9M
100
ORGOOrganogenesis Holdings, Inc.$228.4M
52
SIGASIGA Technologies, Inc.$217.8M
42
CRDLCardiol Therapeutics, Inc.$217.4M
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Emergent BioSolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EBS news & analysis

Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire · 19 Aug 2026negative

Law Offices of Howard G. Smith announced an investigation into Emergent BioSolutions Inc. regarding possible violations of federal securities laws, and is contacting investors who suffered losses in the company's stock to discuss potentially pursuing claims.

Why it matters — A securities fraud investigation and solicitation of investor claims signals potential legal and regulatory risk for Emergent BioSolutions shareholders.

Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Business Wire · 18 Aug 2026negative

The Law Offices of Frank R. Cruz announced a securities fraud investigation into Emergent BioSolutions (NYSE: EBS) on behalf of investors concerning the company's possible violations of federal securities laws. The firm is urging shareholders who lost money to contact it regarding potentially pursuing a claim to recover losses.

Why it matters — A securities fraud investigation signals potential legal and regulatory exposure for Emergent BioSolutions that EBS watchers would want to monitor.

Emergent BioSolutions (EBS) Securities Investigation Notice - Levi & Korsinsky

PRNewsWire · 17 Aug 2026negative

A securities investigation notice has been issued for Emergent BioSolutions by the law firm Levi & Korsinsky. The company reported roughly $97 million in adjusted EBITDA for the quarter, which included a $191.3 million non-cash impairment related to NARCAN.

Why it matters — An EBS watcher would care because the investigation notice, combined with a large non-cash NARCAN impairment, signals potential legal and financial concerns that could weigh on the company's outlook.

EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)

Business Wire · 12 Aug 2026negative

Levi & Korsinsky has notified investors of an investigation into Emergent BioSolutions following a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in naloxone. The firm is encouraging shareholders who suffered losses to come forward with information.

Why it matters — The disclosed non-cash impairment on the NARCAN franchise reflects weakening competitive and pricing conditions in the naloxone market, a key driver for Emergent BioSolutions, and now draws regulatory/legal scrutiny from an investigating firm.

FAQ

Frequently asked questions about EBS stock

What is the EBS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Emergent BioSolutions, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EBS stock a buy right now?

Of the 3 analysts covering Emergent BioSolutions, Inc., 2 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Emergent BioSolutions, Inc. 90 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EBS?

As at 22 Aug 2026, Emergent BioSolutions, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will EBS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +116.1% from the last close, and Ticker Nerd's factor model ranks Emergent BioSolutions, Inc. 90 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EBS stock forecast for 2030?

No analyst covering Emergent BioSolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EBS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $12 over the next 12 months.

How has EBS stock performed over the past year?

Emergent BioSolutions, Inc. returned -45.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Emergent BioSolutions, Inc. do?

Emergent BioSolutions Inc. is a global life sciences company that primarily focuses on the development, manufacturing, and distribution of a wide array of medical products.

What is the latest news on EBS?

The most recent item we track (Business Wire, 19 Aug 2026): "Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation". Law Offices of Howard G. Smith announced an investigation into Emergent BioSolutions Inc. regarding possible violations of federal securities laws, and is contacting investors who suffered losses in the company's stock to discuss potentially pursuing claims.

Company

About Emergent BioSolutions, Inc.

Emergent BioSolutions Inc. is a global life sciences company that primarily focuses on the development, manufacturing, and distribution of a wide array of medical products. These products are designed to address public health threats including chemical and biological agents, and infectious diseases. As an important player in the health sector, the company is known for its specialized work in vaccines, antibody therapeutics, and medical devices. Notably, Emergent BioSolutions is a key supplier of biodefense solutions, including anthrax and smallpox vaccines, which are critical to national security programs. The company’s operations span pharmaceutical manufacturing, research, and development, and it works in partnership with both government and commercial entities. Headquartered in Gaithersburg, Maryland, Emergent BioSolutions plays a pivotal role in emergency preparedness, health security, and response solutions, underscoring its importance in global health initiatives and the broader pharmaceutical industry.

CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph. · 900 employees · United States · https://www.emergentbiosolutions.com